US Patent Issued to Immatics Biotechnologies on April 15 for "In immunotherapy against lung cancer, including NSCLC, SCLC and other cancers" (German Inventors)

ALEXANDRIA, Va., June 5 -- United States Patent no. 12,275,768, issued on April 15, was assigned to Immatics Biotechnologies GmbH (Tubingen, Germany).

"In immunotherapy against lung cancer, including NSCLC, SCLC and other cancers" was invented by Colette Song (Tuebingen, Germany), Oliver Schoor (Tuebingen, Germany), Jens Fritsche (Tuebingen, Germany), Toni Weinschenk (Tuebingen, Germany) and Harpreet Singh (Tuebingen, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tum...